These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 36597957)

  • 1. Investigation on the interaction mechanism of different SARS-CoV-2 spike variants with hACE2: insights from molecular dynamics simulations.
    Wu J; Zhang HX; Zhang J
    Phys Chem Chem Phys; 2023 Jan; 25(3):2304-2319. PubMed ID: 36597957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. E484K mutation in SARS-CoV-2 RBD enhances binding affinity with hACE2 but reduces interactions with neutralizing antibodies and nanobodies: Binding free energy calculation studies.
    Wang WB; Liang Y; Jin YQ; Zhang J; Su JG; Li QM
    J Mol Graph Model; 2021 Dec; 109():108035. PubMed ID: 34562851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity.
    Ou J; Zhou Z; Dai R; Zhang J; Zhao S; Wu X; Lan W; Ren Y; Cui L; Lan Q; Lu L; Seto D; Chodosh J; Wu J; Zhang G; Zhang Q
    J Virol; 2021 Jul; 95(16):e0061721. PubMed ID: 34105996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics.
    Barton MI; MacGowan SA; Kutuzov MA; Dushek O; Barton GJ; van der Merwe PA
    Elife; 2021 Aug; 10():. PubMed ID: 34435953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding the molecular interaction of SARS-CoV-2 spike mutants with ACE2 (angiotensin converting enzyme 2).
    Istifli ES; Netz PA; Sihoglu Tepe A; Sarikurkcu C; Tepe B
    J Biomol Struct Dyn; 2022; 40(23):12760-12771. PubMed ID: 34495817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanistic insights into the effects of key mutations on SARS-CoV-2 RBD-ACE2 binding.
    Aggarwal A; Naskar S; Maroli N; Gorai B; Dixit NM; Maiti PK
    Phys Chem Chem Phys; 2021 Dec; 23(46):26451-26458. PubMed ID: 34806722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RBD Double Mutations of SARS-CoV-2 Strains Increase Transmissibility through Enhanced Interaction between RBD and ACE2 Receptor.
    Sinha S; Tam B; Wang SM
    Viruses; 2021 Dec; 14(1):. PubMed ID: 35062205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Higher infectivity of the SARS-CoV-2 new variants is associated with K417N/T, E484K, and N501Y mutants: An insight from structural data.
    Khan A; Zia T; Suleman M; Khan T; Ali SS; Abbasi AA; Mohammad A; Wei DQ
    J Cell Physiol; 2021 Oct; 236(10):7045-7057. PubMed ID: 33755190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced binding of the N501Y-mutated SARS-CoV-2 spike protein to the human ACE2 receptor: insights from molecular dynamics simulations.
    Luan B; Wang H; Huynh T
    FEBS Lett; 2021 May; 595(10):1454-1461. PubMed ID: 33728680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modeling SARS-CoV-2 spike/ACE2 protein-protein interactions for predicting the binding affinity of new spike variants for ACE2, and novel ACE2 structurally related human protein targets, for COVID-19 handling in the 3PM context.
    Tragni V; Preziusi F; Laera L; Onofrio A; Mercurio I; Todisco S; Volpicella M; De Grassi A; Pierri CL
    EPMA J; 2022 Mar; 13(1):149-175. PubMed ID: 35013687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural Modeling of the SARS-CoV-2 Spike/Human ACE2 Complex Interface can Identify High-Affinity Variants Associated with Increased Transmissibility.
    Gan HH; Twaddle A; Marchand B; Gunsalus KC
    J Mol Biol; 2021 Jul; 433(15):167051. PubMed ID: 33992693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Possible Link between Higher Transmissibility of Alpha, Kappa and Delta Variants of SARS-CoV-2 and Increased Structural Stability of Its Spike Protein and hACE2 Affinity.
    Kumar V; Singh J; Hasnain SE; Sundar D
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In silico binding profile characterization of SARS-CoV-2 spike protein and its mutants bound to human ACE2 receptor.
    Zhang Y; He X; Zhai J; Ji B; Man VH; Wang J
    Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34013346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations of SARS-CoV-2 RBD May Alter Its Molecular Structure to Improve Its Infection Efficiency.
    Alaofi AL; Shahid M
    Biomolecules; 2021 Aug; 11(9):. PubMed ID: 34572486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential inhibitor for blocking binding between ACE2 and SARS-CoV-2 spike protein with mutations.
    Tsai MS; Shih WT; Yang YH; Lin YS; Chang GH; Hsu CM; Yeh RA; Shu LH; Cheng YC; Liu HT; Wu YH; Wu YH; Shen RC; Wu CY
    Biomed Pharmacother; 2022 May; 149():112802. PubMed ID: 35279013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computational decomposition reveals reshaping of the SARS-CoV-2-ACE2 interface among viral variants expressing the N501Y mutation.
    Socher E; Conrad M; Heger L; Paulsen F; Sticht H; Zunke F; Arnold P
    J Cell Biochem; 2021 Dec; 122(12):1863-1872. PubMed ID: 34516024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved Binding Affinity of Omicron's Spike Protein for the Human Angiotensin-Converting Enzyme 2 Receptor Is the Key behind Its Increased Virulence.
    Kumar R; Murugan NA; Srivastava V
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Corilagin and 1,3,6-Tri-
    Binette V; Côté S; Haddad M; Nguyen PT; Bélanger S; Bourgault S; Ramassamy C; Gaudreault R; Mousseau N
    Phys Chem Chem Phys; 2021 Jul; 23(27):14873-14888. PubMed ID: 34223589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GB-2 blocking the interaction between ACE2 and wild type and mutation of spike protein of SARS-CoV-2.
    Tsai MS; Yang YH; Lin YS; Chang GH; Hsu CM; Yeh RA; Shu LH; Cheng YC; Liu HT; Wu YH; Wu YH; Shen RC; Wu CY
    Biomed Pharmacother; 2021 Oct; 142():112011. PubMed ID: 34388530
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 24.